title: [Haemorrhagic fever viruses, possible bioterrorist use].
abstract: The majority of haemorrhagic fever viruses are responsible for various clinical manifestations, the mutual characteristics of which are fever and haemorrhage in 5 to 70% of cases. All degrees of severity can be observed, ranging from isolated fever to multi-organ failure and death. These viruses belong to one of the following families: filoviridae, arenaviridae, bunyaviridae, and flaviviridae. They must be considered as dangerous biological weapons that could potentially be used. Most of the viruses responsible for haemorrhagic fever can be transmitted to humans through the air in spray form, except the dengue virus and the agents of haemorrhagic fever from the Congo Crimea and the haemorrhagic fever with renal syndrome that are difficult to handle in cell culture. In the event of a bioterrorist act, the management of persons infected or suspected of being so will be made by the referent departments of infectious diseases, defined by the French Biotox plan. Management includes isolation, confirmation or invalidation of the diagnosis and rapid initiation of treatment with ribavirin. Ribavirin is recommended for the treatment and prophylaxis of arenavirus and bunyavirus infections; it is not effective for the other families of virus. Except for yellow fever, there is no vaccination for the other forms of viral haemorrhagic fever.
authors.affiliation: Service des maladies infectieuses et tropicales, Groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Rigaudeau
authors.forename: François
authors.initials: F
authors.lastname: Bricaire
authors.forename: Philippe
authors.initials: P
authors.lastname: Bossi
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D001116:Arenaviridae / Q000145:classification / Q000472:pathogenicity; D023482:Bioterrorism / Q000517:prevention & control* / Q000706:statistics & numerical data; D002043:Bunyaviridae / Q000145:classification / Q000472:pathogenicity; D003140:Communicable Disease Control / Q000458:organization & administration; D004189:Disaster Planning / Q000458:organization & administration; D004632:Emergency Medical Services / Q000458:organization & administration; D016563:Filoviridae / Q000145:classification / Q000472:pathogenicity; D018067:Flaviviridae / Q000145:classification / Q000472:pathogenicity; D005602:France / Q000453:epidemiology; D006482:Hemorrhagic Fevers, Viral / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D006801:Humans; D012254:Ribavirin / Q000627:therapeutic use; D012720:Severity of Illness Index; D014611:Vaccination
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin